Return to Mayo Clinic Q&A

Cardiac risks of off-label drugs to treat COVID-19

By Jennifer O'Hara • April 8, 2020

Cardiac risks of off-label drugs to treat COVID-19
April 8, 2020

A study published recently in Mayo Clinic Proceedings details information about potential cardiac side effects when using off-label drugs to treat COVID-19. Off-label means the drug has been approved by the Food and Drug Administration to treat a different condition. Some of the off-label drugs being used to treat COVID-19 have a risk of sudden cardiac arrest and death. 

On the Mayo Clinic Q&A podcast, Dr. Michael Ackerman, a Mayo Clinic genetic cardiologist and director of the  Windland Smith Rice Sudden Death Genomics Laboratory, explains how heart monitoring is important to identify at-risk patients.

Related Episodes
Advancing treatments for acute myeloid leukemia

Advancing treatments for acute myeloid leukemiaDecember 20, 2022 Acute myeloid leukemia (AML), also called acute myelogenous leukemia, is a cancer of the blood and bone marrow,[...]

By Jennifer O'Hara • December 20, 2022
Tips for living younger, longer by preventing disease

Tips for living younger, longer by preventing diseaseDecember 16, 2022 While we know that health affects longevity and quality of life, it can be difficult[...]

By Jennifer O'Hara • December 16, 2022
Understanding pituitary tumors

Understanding pituitary tumorsDecember 13, 2022 Pituitary tumors are abnormal growths that develop in your pituitary gland. Pituitary tumors can cause too much or too little of[...]

By Jennifer O'Hara • December 13, 2022